# Shanghai Fudan-Zhangjiang trials: 25

ClinicalTrials.gov lists 25 trials with Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. as lead sponsor, 4 of them recruiting or not yet recruiting.

## The full list

Clinical trials led by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.: 25 rows for $5, every trial on ClinicalTrials.gov. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/shanghai-fudan-zhangjiang-bio-pharmaceutical-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 25
- Recruiting or not yet: 4
- Read on: November 19, 2026

## Trials

The 25 newest of 25, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| March 6, 2026 | NCT07455045 | A Phase I Study of FZ-AD005 in Patients With High-Grade Glioma (HGG) | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Phase 1 | Not yet recruiting | High Grade Glioma (III or IV), Diffuse Midline Glioma (DMG), Glioblastoma (GBM) | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07455045) |
| December 4, 2024 | NCT06715319 | Obeticholic Acid Versus Placebo, in Combination with Ursodeoxycholic Acid in Patients with Primary Biliary Cirrhosis | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Phase 3 | Completed | PBC | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06715319) |
| July 25, 2024 | NCT06519370 | FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Phase 3 | Active not recruiting | Triple Negative Breast Cancer | 350 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06519370) |
| June 3, 2024 | NCT06439433 | ALA-PDT in Patients With CIN2 in p16-positivity and High-risk HPV Infection | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Phase 2 | Completed | Cervical Intraepithelial Neoplasia Grade 2, Papillomavirus Infections, p16 Protein | 119 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06439433) |
| May 22, 2024 | NCT06424665 | A Study of FZ-AD005 in Patients With Advanced Solid Tumors | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Phase 1 | Recruiting | Advanced Solid Tumor, SCLC(Small Cell Lung Cancer) or LCNEC (Large Cell Neuroendocrine Carcinoma) | 162 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06424665) |
| May 16, 2024 | NCT06417281 | Photodynamic Diagnosis for Malignant Brain Glioma With 5-Aminolevulinic Acid（5-ALA） | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Phase 3 | Completed | 5-aminolevulinic Acid, Malignant Glioma of Brain | 86 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06417281) |
| May 14, 2024 | NCT06413615 | A Study of FDA022-BB05 in Advanced/Metastatic Solid Tumors | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Phase 2 | Unknown | Advanced Solid Tumor | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06413615) |
| June 22, 2023 | NCT05914545 | A Study of FZ-AD004 in Patients With Advanced Solid Tumors | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Phase 1 | Recruiting | Advanced and Metastatic Solid Tumor | 121 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05914545) |
| October 4, 2022 | NCT05564858 | A Study of FDA022-BB05 in Subjects With Advanced Solid Malignant Tumors | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Phase 1 | Unknown | Advanced Solid Tumors | 107 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05564858) |
| January 3, 2022 | NCT05174637 | A Study of FDA018-ADC in Patients With Advanced Solid Tumors | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Phase 1 | Active not recruiting | Advanced/ Metastatic Solid Tumors | 78 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05174637) |
| December 29, 2021 | NCT05171894 | A Study to Evaluate Efficacy and Safety of Light Dose in Subjects With PWB Treated With Hemoporfin PDT | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Phase 2 | Recruiting | Port-wine Birthmarks, Port-Wine Stain, Nevus Flammeus | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05171894) |
| January 20, 2021 | NCT04715529 | Phase 1 Study to Evaluate Safety and Pharmacokinetics of FZJ-003 in Healthy Volunteers | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Phase 1 | Completed | Healthy Volunteers | 62 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04715529) |
| September 27, 2019 | NCT04106258 | A Pilot Study of Hemoporfin PDT in Children(2-7 Years Old) With Port-wine Stain | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Phase 4 | Completed | Port-wine Stain | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04106258) |
| August 5, 2019 | NCT04044898 | Pharmacokinetics and Safety of ALA in Acne Vulgaris | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Phase 1 | Completed | Acne Vulgaris | 19 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04044898) |
| July 15, 2019 | NCT04018885 | A Study on Safety and Preliminary Efficacy of ALA in Acne Vulgaris | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Phase 1/2 | Completed | Acne Vulgaris | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04018885) |
| March 28, 2019 | NCT03894150 | A Study of F0002-ADC in Chinese Patients With Refractory or Recurrent CD30+ Hematologic Malignancies. | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Phase 1 | Completed | Refractory or Recurrent CD30+ Hematologic Malignancies | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03894150) |
| June 9, 2017 | NCT03181984 | Postmarketing Safety Study of Hemoporfin in Patients With Port Wine Stain | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Phase 4 | Completed | Port-Wine Stain | 501 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03181984) |
| April 24, 2017 | NCT03125057 | A Pilot Study of Hemoporfin PDT in Children With Port-wine Stain | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Phase 4 | Completed | Port-wine Stain | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03125057) |
| November 4, 2016 | NCT02955771 | Efficacy and Safety Study of PDT Using Deuteporfin for Unresectable Advanced Perihilar Cholangiocarcinoma | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Phase 2 | Terminated | Hilar Cholangiocarcinoma | 7 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02955771) |
| December 16, 2015 | NCT02631863 | Aminolaevulinic Acid Photodynamic Therapy for HPV+ Low Grade Cervical Intraepithelial Neoplasia (LSIL;CIN1) | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Phase 2 | Completed | Cervical Intraepithelial Neoplasia, Low-Grade Squamous Intraepithelial Lesions, Papillomavirus Infections | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02631863) |
| June 25, 2015 | NCT02481180 | Tolerance, Pharmacokinetics and Preliminary Efficacy of T0001 in RA (Rheumatoid Arthritis) | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Phase 1 | Terminated | Rheumatoid Arthritis | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02481180) |
| December 2, 2014 | NCT02304770 | Aminolaevulinic Acid Photodynamic Therapy of Cervical Persistent HPV Infection and Cervical Neoplasia | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Phase 2 | Completed | Cervical Persistent High Risk HPV Infection, Cervical Intraepithelial Neoplasia | 73 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02304770) |
| November 14, 2014 | NCT02291471 | Tolerance and Pharmacokinetics of T0001 in Healthy Adult Chinese Volunteers | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Phase 1 | Completed | Rheumatic Diseases | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02291471) |
| September 11, 2014 | NCT02237690 | Assess Bioequivalence of Two Formulations of Doxorubicin Hydrochloride Liposome in Female Patients With Ovarian Cancer | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Phase 1 | Completed | Ovarian Cancer | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02237690) |
| November 29, 2011 | NCT01481597 | Deuteporfin Tolerance and Pharmacokinetics in Healthy Volunteers | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Phase 1 | Completed | Healthy | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01481597) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 12 |
| Phase 1/2 | 1 |
| Phase 2 | 6 |
| Phase 3 | 3 |
| Phase 4 | 3 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 15 |
| Recruiting | 3 |
| Unknown | 2 |
| Terminated | 2 |
| Active not recruiting | 2 |
| Not yet recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Port-Wine Stain | 4 |
| Uterine Cervical Dysplasia | 2 |
| Papillomavirus Infections | 2 |
| Acne Vulgaris | 2 |
| Neoplasms | 1 |
| Arthritis, Rheumatoid | 1 |
| Squamous Intraepithelial Lesions | 1 |
| Ovarian Neoplasms | 1 |
| Triple Negative Breast Neoplasms | 1 |
| Small Cell Lung Carcinoma | 1 |
| Klatskin Tumor | 1 |
| Neoplasm Metastasis | 1 |
| Glioma | 1 |
| Glioblastoma | 1 |
| Rheumatic Diseases | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Inventory control companies in the United States](https://specstream.ai/data/businesses/inventory-control-companies/united-states)
- [Indonesian restaurants in the United States](https://specstream.ai/data/businesses/indonesian-restaurants/united-states)
- [HR services firms in the United States](https://specstream.ai/data/businesses/hr-services-firms/united-states)
- [Home network installers in the United States](https://specstream.ai/data/businesses/home-network-installers/united-states)
- [Hardware and fastener manufacturers in the United States](https://specstream.ai/data/businesses/hardware-and-fastener-manufacturers/united-states)
